Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT03888105Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Jun 2026
- Countries
- 14
01
Overview
Phase 2, open-label trial of odronextamab in B-cell non-Hodgkin lymphoma (5 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Objective Response Rate at 52 weeks. Started Nov 2019; status: active, not recruiting.
02
Drugs
odronextamab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03888105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888105.